RE-BVS – Piemonte Repository

Sfoglia per AUTORE
MALGERI A
Collezione ASL Cuneo 2

Items : 5

Prognostic Impact of IMDC Category Shift From Baseline to Nivolumab Initiation in Metastatic Renal Cell Carcinoma: A Sub-Analysis of the MEET-URO 15 Study. in Clinical genitourinary cancer / Clin Genitourin Cancer. 2025 Feb;23(1):102267. doi: 10.1016/j.clgc.2024.102267. Epub 2024 Nov 10.

2025
ASL Cuneo 2
AO Ordine Mauriziano

Puglisi S; Lipari H; Cavo A; Vignani F; Nolè F; Prati G; Morelli F; Spada M; Caffo O; Napoli MD; Atzori F; Malgeri A; Prati V; Sorarù M; Tudini M; Mollica V; Ricotta R; Baldessari C; Fratino L; Merler S; Procopio G; Naglieri E; Masini C; Zucali PA; Galli L; Sbrana A; Chiellino S; De Giorgi U; Maruzzo M; et alii...

Prognostic value of type of prior TKI in pretreated metastatic renal cell carcinoma patients receiving nivolumab. in Immunotherapy / Immunotherapy. 2024;16(18-19):1095-1103. doi: 10.1080/1750743X.2024.2385881. Epub 2024 Aug 19.

2024
ASL Cuneo 2
AO Ordine Mauriziano

Murianni V; Catalano F; Nolè F; Prati G; Morelli F; Messina M; Atzori F; Tudini M; Prati V; Roviello G; Cavo A; Vignani F; Caffo O; Napoli MD; Malgeri A; Rebuzzi SE; Signori A; Cremante M; Damassi A; Rescigno P; Banna GL; Fornarini G; Buti S;

Sodium levels and immunotherapy efficacy in mRCC patients with bone metastases: sub analysis of Meet-Uro 15 study. in Frontiers in immunology / Front Immunol. 2024 Jul 5;15:1361010. doi: 10.3389/fimmu.2024.1361010. eCollection 2024.

2024
ASL Cuneo 2
AO Ordine Mauriziano

Naglieri E; Malgeri A; Cavo A; Di Napoli M; Vignani F; Nolè F; Prati G; Morelli F; Atzori F; Caffo O; Prati V; Fratino L; Tudini M; Mollica V; Sorarù M; Ricotta R; Pipitone S; Zampiva I; Chiellino S; Claps M; Fornarini G; Zucali PA; Galli L; Buti S; De Giorgi U; Maruzzo M; Rebuzzi SE; Catalano M; Signori A; et alii...

Time to strategy failure and treatment beyond progression in pretreated metastatic renal cell carcinoma patients receiving nivolumab: post-hoc analysis of the Meet-URO 15 study. in Frontiers in oncology / Front Oncol. 2024 Feb 12;14:1307635. doi: 10.3389/fonc.2024.1307635. eCollection 2024.

2024
ASL Cuneo 2
AO Ordine Mauriziano

Roviello G; Lipari H; Cavo A; Vignani F; Nolè F; Prati G; Morelli F; Spada M; Caffo O; Di Napoli M; Atzori F; Malgeri A; Prati V; Sorarù M; Tudini M; Mollica V; Ricotta R; Baldessari C; Fratino L; Milella M; Procopio G; Naglieri E; Masini C; Zucali PA; Galli L; Chiellino S; Bimbatti D; De Giorgi U; Rebuzzi SE; et alii...

Pembrolizumab Plus Axitinib for Metastatic Papillary and Chromophobe Renal Cell Carcinoma: NEMESIA (Non Clear MEtaStatic Renal Cell Carcinoma Pembrolizumab Axitinib) Study, a Subgroup Analysis of I-RARE Observational Study (Meet-URO 23a). in International journal of molecular sciences / Int J Mol Sci. 2023 Jan 6;24(2):1096. doi: 10.3390/ijms24021096.

2023
ASL Cuneo 2

Stellato M; Buti S; Maruzzo M; Bersanelli M; Pierantoni F; De Giorgi U; Di Napoli M; Iacovelli R; Vitale MG; Ermacora P; Malgeri A; Maiorano BA; Prati V; Mennitto A; Cavo A; Santoni M; Carella C; Fratino L; Procopio G; Verzoni E; Santini D;